918164-16-6

Basic information

• Product Name: methyl 4-acetoxy-3-(3-methylbut-2-enyl)benzoate
• Synonyms: methyl 4-acetoxy-3-(3-methylbut-2-enyl)benzoate
• CAS NO: 918164-16-6
• Molecular Weight: 262.306
• Mol File: 918164-16-6.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: methyl 4-acetoxy-3-(3-methylbut-2-enyl)benzoate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 4-acetoxy-3-(3-methylbut-2-enyl)benzoate(918164-16-6)
• EPA Substance Registry System: methyl 4-acetoxy-3-(3-methylbut-2-enyl)benzoate(918164-16-6)

Safety Data

• Hazardous Substances Data: 918164-16-6(Hazardous Substances Data)

Upstream product

• 513-35-9 2-methyl-but-2-ene 
• 96042-30-7 4-(dicyanomethylene)-2-methyl-6-(p-dimethylaminostyryl)-4H-pyran 
• 108-95-2 phenol 
• 35750-24-4 methyl 4-allyloxybenzoate 
• 53596-60-4 methyl 3-allyl-4-hydroxybenzoate 
• 918164-15-5 methyl 4-acetoxy-3-allylbenzoate 

Downstream Products

• 1990-85-8 4-acetoxy-3-(3-methylbut-2-en-1-yl)benzoic acid 
• 92194-92-8 4-(chlorocarbonyl)-2-(3-methylbut-2-en-1-yl)phenyl acetate 
• 918164-17-7 4-((7-((3aR,4R,7R,7aR)-7-methoxy-6,6-dimethyl-2-oxotetrahydro-3aH-[1.3]dioxolo[4,5-c]pyran-4-yloxy)-8-methyl-2-oxo-2H-chromen-3-ylcarbamoyl)-2-(3-methylbut-2-enyl) phenyl acetate 
• 1138-41-6 4-hydroxy-3-prenylbenzoic acid 

Relevant articles and documents

NOVOBIOCIN ANALOGUES AND TREATMENT OF POLYCYSTIC KIDNEY DISEASE

Novobiocin analogues are useful in methods of treating, inhibiting, and/or preventing cyst formation in autosomal dominant polycystic kidney disease (ADPKD) in a subject. The disclosure provides methods of treating ADPKD comprising administering a therapeutically effective amount of a coumarin-3-carboxamide novobiocin analogue. Accordingly, the method can include administering a novobiocin analogue in a therapeutically effective amount for reducing levels of mTOR pathway phosphoproteins P-mTOR, P-Akt and P-S6K, or combinations thereof. Further, the method can include administering a novobiocin analogue in a therapeutically effective amount for reducing levels of Hsp-90 client proteins CFTR, ErbB2, c-Raf and Cdk4, or combinations thereof.